Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment

Daan W Huntjens; Joost W Vanhommerig; Willem van de Veen; Mirjam Crul

doi:10.1001/jamaoncol.2023.4821

Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment

JAMA Oncol. 2024 Jan 1;10(1):131-132. doi: 10.1001/jamaoncol.2023.4821.

Authors

Daan W Huntjens^{1

2}, Joost W Vanhommerig³, Willem van de Veen⁴, Mirjam Crul¹

Affiliations

¹ Department of Clinical Pharmacology and Pharmacy, Amsterdam University Medical Center, Amsterdam, the Netherlands.
² Department of Clinical Pharmacy, OLVG Hospital, Amsterdam, the Netherlands.
³ Department of Research and Epidemiology, OLVG Hospital, Amsterdam, the Netherlands.
⁴ Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.

No abstract available

Plain language summary

This cohort study conducted in the Netherlands uses electronic medical records to assess incidence of hypersensitivity reactions with and without H2-receptor antagonist premedication before paclitaxel administration.

MeSH terms

Dexamethasone / therapeutic use
Humans
Infusions, Intravenous
Paclitaxel* / adverse effects
Premedication
Ranitidine* / adverse effects

Substances

Paclitaxel
Ranitidine
Dexamethasone